Does Sharp Health Plan Cover Vyvanse?

The Short Answer: Coverage Is Plan- and Product-Specific

"Vyvanse" can mean the brand product or, informally, lisdexamfetamine treatment. Those are not always handled the same way by a formulary.

Sharp publishes different formularies for Individual and Family coverage, employer plans, PPO plans, federal employees, and Medicare products. A rule found in one document should not be presented as universal across all Sharp members.

The cited 2026 formularies show:

• The 2026 Individual and Family formulary, effective August 1, 2026, lists generic lisdexamfetamine capsules and chewable tablets as Tier 1 with quantity limits and mail-order availability. The entries do not show a prior-authorization marker.
• The 2026 commercial PPO formulary, effective August 1, 2026, lists generic lisdexamfetamine capsules and chewable tablets as Tier 1 with quantity limits and prior authorization required for age 19 and older.
• Brand Vyvanse is not listed by name in those two documents. Under the formularies' own instructions, a drug absent from the list is nonformulary unless covered through an exception or another plan-specific rule.

No single PA rule or copay applies to every Sharp member.

How to Check Your Exact Sharp Coverage

Use Sharp's pharmacy benefits and drug-list page and select the formulary that matches the plan name on your member card. Search separately for:

1. Vyvanse
2. lisdexamfetamine dimesylate capsule
3. lisdexamfetamine dimesylate chewable tablet, if that is the prescribed form

Then read all codes next to the exact strength and form. Sharp uses abbreviations such as PA for prior authorization, QL for quantity limit, ST for step therapy, and MO for mail order.

For an individualized price, Sharp directs members to its CVS Caremark Drug Cost & Coverage tool. A Tier 1 listing alone does not reveal the final price because deductibles, pharmacy network, supply length, and benefit design can change what a member pays.

Does Sharp Require Prior Authorization?

Sometimes, but not under every plan.

The current PPO list applies PA to generic lisdexamfetamine for adults age 19 and older. The current Individual and Family list shows quantity limits but no PA marker on the generic entries. Other Sharp formularies can apply different requirements.

If PA is required, the prescriber should respond to the criteria requested by the plan rather than rely on a generic template. Useful records can include the diagnosis, indication, requested dosage form, treatment history, response, adverse effects, and the clinical reason for the requested product.

A PA marker does not, by itself, disclose the plan's approval criteria. Members and prescribers should use the exact plan's criteria rather than assume one universal list of required alternatives or step-therapy rules.

What If Brand Vyvanse Is Not Listed?

Sharp's commercial formulary instructions say that a member, authorized representative, or prescriber may request a formulary exception when a nonformulary drug is medically necessary. The request follows the pharmacy prior-authorization process and should include supporting information.

The documents state that, after required supporting information is received, a formulary-exception decision is made within 72 hours for a non-urgent request or within 24 hours for an urgent or exigent request. Those timeframes concern the exception request described in the formulary; they should not be generalized to every kind of claim or appeal.

Sharp provides a pharmacy prior-authorization and step-therapy exception form. A member or prescriber can also use the contact route on the member card to confirm where to send records.

Brand Versus Generic Lisdexamfetamine

FDA approved the first generic versions of Vyvanse in August 2023. The agency's generic-approval announcement identifies the approved capsule and chewable-tablet products and their indications.

The FDA approval record does not mean every member experiences the same availability or pharmacy inventory. It also does not prove that a brand exception will be approved. If a patient and prescriber report a clinically important problem with a particular product, the documentation should describe the actual response and the reason for requesting a different product.

Approved Uses and the Evidence Behind Lisdexamfetamine

Current FDA labeling should control the indication and dosing discussion. The current Vyvanse label in DailyMed identifies indications for ADHD in adults and pediatric patients age 6 and older, and for moderate-to-severe binge-eating disorder in adults. The label also contains boxed-warning, contraindication, interaction, cardiovascular, psychiatric, growth, and dosing information.

For ADHD, the exact PubMed record "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults" is a systematic review and network meta-analysis of randomized trials. It supports stimulant efficacy while also showing that age group, tolerability, and evidence horizon matter; it does not establish what Sharp must cover.

For binge-eating disorder, "Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial" supports the adult indication. The FDA generic-approval page confirms the corresponding approved generic forms and indications. Neither source is a formulary promise or a substitute for the plan's criteria.

For children and adolescents with ADHD, the American Academy of Pediatrics guideline has the exact title "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". It addresses evidence-based care, not Sharp's administrative rules.

What Will It Cost?

There is no single Sharp copay for Vyvanse or generic lisdexamfetamine. The member-specific price depends on the plan, deductible, pharmacy network, supply length, and current benefit design.

To get an actionable estimate:

1. Confirm whether the prescription is brand or generic and capsule or chewable.
2. Confirm the drug's current tier and requirements in the exact plan formulary.
3. Use the member cost tool with the intended pharmacy and supply length.
4. Ask whether the deductible applies and whether the pharmacy is preferred or in network.
5. Recheck the price if the pharmacy substitutes a different manufacturer or if coverage changes.

Manufacturer programs change and can exclude government-insured patients. Verify any current offer and dollar amount on the manufacturer's official site.

How to Respond to a Denial

First, obtain the written reason. A denial can reflect missing PA information, a quantity limit, a nonformulary brand request, an age rule, an early refill, or a benefit exclusion. Each requires a different response.

• Missing information: the prescriber can submit the requested clinical documentation.
• PA denial: compare the decision with the plan's stated criteria and submit the relevant evidence.
• Nonformulary brand: request a formulary exception and explain why the listed generic does not meet the patient's needs.
• Quantity-limit issue: request the exact quantity exception if the prescribed amount is clinically necessary.
• Appeal: follow the instructions and deadline in the denial notice; Sharp's formulary states that a denied exception can be appealed.

For California plans regulated by the Department of Managed Health Care, the state's prescription-drug rights page explains how to complain to the plan and, when applicable, seek help from the DMHC. Medicare, self-funded employer coverage, and other arrangements may use different external-review routes, so identify the plan type before relying on that process.

Appeal deadlines and review procedures are not universal. Use the deadline and instructions in the member's governing plan document and denial notice.